Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Entrada Therapeutics (TRDA) Revenue (2023 - 2025)

Entrada Therapeutics has reported Revenue over the past 3 years, most recently at $1.3 million for Q4 2025.

  • Quarterly results put Revenue at $1.3 million for Q4 2025, down 96.53% from a year ago — trailing twelve months through Dec 2025 was $25.4 million (down 87.94% YoY), and the annual figure for FY2025 was $25.4 million, down 87.94%.
  • Revenue for Q4 2025 was $1.3 million at Entrada Therapeutics, down from $1.6 million in the prior quarter.
  • Over the last five years, Revenue for TRDA hit a ceiling of $94.7 million in Q2 2024 and a floor of $1.3 million in Q4 2025.
  • Median Revenue over the past 3 years was $22.9 million (2023), compared with a mean of $30.4 million.
  • Biggest five-year swings in Revenue: soared 421.16% in 2024 and later crashed 97.94% in 2025.
  • Entrada Therapeutics' Revenue stood at $41.8 million in 2023, then decreased by 10.63% to $37.4 million in 2024, then tumbled by 96.53% to $1.3 million in 2025.
  • The last three reported values for Revenue were $1.3 million (Q4 2025), $1.6 million (Q3 2025), and $2.0 million (Q2 2025) per Business Quant data.